MktsMarkets

Nurix Therapeutics, Inc.
NASDAQ: NRIXKey statistics
NRIX News
Stories mentioning NRIX from around the web — every one is an open thread, so give it a like or add your take.
Loading news…
Financial statements
As filed, straight from the 10-Q — up to 19 years of history, free, with every line item chartable.
| Line item | Q2 '26May 31 | Q1 '26Feb 28 | Q4 '25Nov 30 | Q3 '25Aug 31 | Q2 '25May 31 | Q1 '25Feb 28 | Q4 '24Nov 30 | Q3 '24Aug 31 |
|---|---|---|---|---|---|---|---|---|
| Income Statement | ||||||||
| Revenue | 9,043 | 6,252 | 13,577 | 7,894 | 44,056 | 18,453 | 13,284 | 12,588 |
| Cost of Goods Sold | ||||||||
| Gross Profit | ||||||||
| Operating Expenses | ||||||||
| Research & Development | 87,653 | 84,137 | 83,024 | 86,120 | 78,096 | 69,663 | 67,224 | 55,481 |
| Sales General & Admin | ||||||||
| Total Operating Expenses | 103,247 | 98,747 | 96,672 | 99,279 | 92,378 | 81,317 | 77,941 | 67,199 |
| Operating Income (Loss) | (94,204) | (92,495) | (83,095) | (91,385) | (48,322) | (62,864) | (64,657) | (54,611) |
| Interest Income | ||||||||
| Interest Expense | ||||||||
| Other Expense | ||||||||
| Pretax Income | (89,806) | (78,221) | (86,421) | (42,704) | (56,351) | (58,541) | (48,874) | |
| Tax Provision | (271.00) | 0.00 | 0.00 | 0.00 | 760.00 | 0.00 | 8.00 | 82.00 |
| Net Income (Loss) | (89,535) | (87,174) | (78,221) | (86,421) | (43,464) | (56,351) | (58,549) | (48,956) |
| Earnings Per Share (Basic) | (0.81) | (0.79) | (0.90) | (1.03) | (0.52) | (0.67) | (0.87) | (0.67) |
| Earnings Per Share (Diluted) | (0.81) | (0.79) | (0.90) | (1.03) | (0.52) | (0.67) | (0.87) | (0.67) |
| Weighted Average Shares Outstanding (Basic) | 111,084 | 110,072 | 86,667 | 84,159 | 83,882 | 83,561 | 67,120 | 72,779 |
| Weighted Average Shares Outstanding (Diluted) | 111,084 | 110,072 | 86,667 | 84,159 | 83,882 | 83,561 | 67,120 | 72,779 |
Scroll the table sideways for older periods — the line-item column and the period header stay put. Hover a row and use the chart handle to plot it over the full history.
About NRIX
Nurix Therapeutics, Inc. (NASDAQ: NRIX) is a stock listed on the Nasdaq Stock Market under the ticker symbol NRIX. It last traded at $14.73 (Nov 16, 2026, 4:00 PM ET), down 4.8% on the day. That gives Nurix Therapeutics a market capitalisation of $1.7B and a price-to-earnings ratio of 5.7.
Over the past 52 weeks NRIX has traded between $12.01 and $28.23.
Revenue for the quarter ended May 31, 2026 was $9.0M; a net loss of $89.5M. Revenue was down 79.5% from $44.1M in the quarter ended May 31, 2025.
| Quarter ended | Revenue | Net income | Margin |
|---|---|---|---|
| May 31, 2026 | $9.0M | -$89.5M | -990.1% |
| Feb 28, 2026 | $6.3M | -$87.2M | -1394.3% |
| Nov 30, 2025 | $13.6M | -$78.2M | -576.1% |
| Aug 31, 2025 | $7.9M | -$86.4M | -1094.8% |
From Nurix Therapeutics’s quarterly (10-Q) filings, in US dollars.
Take a break — play a market game
Seven free games built around the markets. No download, no sign-up: they run right here in your browser.
Latest News
Market news from around the web — every story is an open thread, so give it a like or add your take.
Loading news…